These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

73 related articles for article (PubMed ID: 21871865)

  • 1. Optimal design for the dose-response screening of tight-binding enzyme inhibitors.
    Kuzmič P
    Anal Biochem; 2011 Dec; 419(2):117-22. PubMed ID: 21871865
    [TBL] [Abstract][Full Text] [Related]  

  • 2. High-throughput screening of enzyme inhibitors: automatic determination of tight-binding inhibition constants.
    Kuzmic P; Sideris S; Cregar LM; Elrod KC; Rice KD; Janc JW
    Anal Biochem; 2000 May; 281(1):62-7. PubMed ID: 10847611
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Determination of accurate KI values for tight-binding enzyme inhibitors: an in silico study of experimental error and assay design.
    Murphy DJ
    Anal Biochem; 2004 Apr; 327(1):61-7. PubMed ID: 15033511
    [TBL] [Abstract][Full Text] [Related]  

  • 4. High-throughput screening of enzyme inhibitors: simultaneous determination of tight-binding inhibition constants and enzyme concentration.
    Kuzmic P; Elrod KC; Cregar LM; Sideris S; Rai R; Janc JW
    Anal Biochem; 2000 Nov; 286(1):45-50. PubMed ID: 11038272
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Optimal adaptive design in clinical drug development: a simulation example.
    Maloney A; Karlsson MO; Simonsson US
    J Clin Pharmacol; 2007 Oct; 47(10):1231-43. PubMed ID: 17906158
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Optimal experimental design for assessment of enzyme kinetics in a drug discovery screening environment.
    Sjögren E; Nyberg J; Magnusson MO; Lennernäs H; Hooker A; Bredberg U
    Drug Metab Dispos; 2011 May; 39(5):858-63. PubMed ID: 21289074
    [TBL] [Abstract][Full Text] [Related]  

  • 7. High-throughput screening of enzyme inhibition using an inhibitor gradient generated in a microchannel.
    Garcia E; Hasenbank MS; Finlayson B; Yager P
    Lab Chip; 2007 Feb; 7(2):249-55. PubMed ID: 17268628
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Calculating the probability of detection for inhibitors in enzymatic or binding reactions in high-throughput screening.
    Buxser S; Vroegop S
    Anal Biochem; 2005 May; 340(1):1-13. PubMed ID: 15802124
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Optimal serial dilutions designs for drug discovery experiments.
    Donev AN; Tobias RD
    J Biopharm Stat; 2011 May; 21(3):484-97. PubMed ID: 21442521
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Potential application of D-optimal designs in the efficient investigation of cytochrome P450 inhibition kinetic models.
    Youdim KA; Atkinson AC; Patan M; Bogacka B; Johnson PJ
    Drug Metab Dispos; 2010 Jul; 38(7):1019-23. PubMed ID: 20400659
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Optimal experimental design with the sigma point method.
    Schenkendorf R; Kremling A; Mangold M
    IET Syst Biol; 2009 Jan; 3(1):10-23. PubMed ID: 19154081
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Defining balanced conditions for inhibitor screening assays that target bisubstrate enzymes.
    Yang J; Copeland RA; Lai Z
    J Biomol Screen; 2009 Feb; 14(2):111-20. PubMed ID: 19196704
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Identification of small-molecule inhibitors of human angiogenin and characterization of their binding interactions guided by computational docking.
    Jenkins JL; Shapiro R
    Biochemistry; 2003 Jun; 42(22):6674-87. PubMed ID: 12779322
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Efficient elimination of nonstoichiometric enzyme inhibitors from HTS hit lists.
    Habig M; Blechschmidt A; Dressler S; Hess B; Patel V; Billich A; Ostermeier C; Beer D; Klumpp M
    J Biomol Screen; 2009 Jul; 14(6):679-89. PubMed ID: 19470716
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Design and analysis of in vitro antitumor pharmacodynamic studies.
    Kalns JE; Millenbaugh NJ; Wientjes MG; Au JL
    Cancer Res; 1995 Nov; 55(22):5315-22. PubMed ID: 7585594
    [TBL] [Abstract][Full Text] [Related]  

  • 16. A graphical method for determining inhibition constants.
    Yoshino M; Murakami K
    J Enzyme Inhib Med Chem; 2009 Dec; 24(6):1288-90. PubMed ID: 19912063
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Optimal design of the chronic animal bioassay.
    Portier C; Hoel D
    J Toxicol Environ Health; 1983 Jul; 12(1):1-19. PubMed ID: 6631999
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Interpreting steep dose-response curves in early inhibitor discovery.
    Shoichet BK
    J Med Chem; 2006 Dec; 49(25):7274-7. PubMed ID: 17149857
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Structure-based optimization of a potent class of arylamide FMS inhibitors.
    Meegalla SK; Wall MJ; Chen J; Wilson KJ; Ballentine SK; Desjarlais RL; Schubert C; Crysler CS; Chen Y; Molloy CJ; Chaikin MA; Manthey CL; Player MR; Tomczuk BE; Illig CR
    Bioorg Med Chem Lett; 2008 Jun; 18(12):3632-7. PubMed ID: 18495479
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Adaptive-optimal design in PET occupancy studies.
    Zamuner S; Di Iorio VL; Nyberg J; Gunn RN; Cunningham VJ; Gomeni R; Hooker AC
    Clin Pharmacol Ther; 2010 May; 87(5):563-71. PubMed ID: 20336064
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 4.